It is suggested that JRRs provide a complementary approach to UniRIs by capturing abnormal joint biomarker configurations in high-dimensional proteomics data by capturing abnormal joint biomarker configurations in high-dimensional proteomics data.
Abstract
Conventional univariate reference intervals (UniRIs) are widely used to identify abnormal biomarker values, but they evaluate each biomarker independently and do not account for coordinated deviations between biomarkers. We developed and evaluated a joint reference region (JRR) framework for plasma proteomics data using the Olink proteomics dataset generated by the UK Biobank Pharma Proteomics Project, covering approximately 3,000 plasma proteins. JRRs were estimated for selected protein pairs in a healthy reference subset, while UniRIs were estimated separately for individual proteins using the nonparametric method. Both approaches were then evaluated in ICD-defined disease subsets. Biomarker discovery revealed sparse and heterogeneous disease--protein associations, with some proteins recurring across multiple phenotypes and others showing more disease-specific patterns. The added value of JRRs varied across diseases and protein pairs. Across evaluated protein pairs, 56.5% showed higher sensitivity under the JRR framework than the UniRI of the first protein, and 47.3% showed higher sensitivity than the UniRI of the second protein. At the disease level, the median proportion of protein pairs with improved JRR sensitivity was 0.57. JRRs were most informative when univariate detection was limited but a subset of diseased observations was flagged only by the joint region. These findings suggest that JRRs provide a complementary approach to UniRIs by capturing abnormal joint biomarker configurations in high-dimensional proteomics data.
Large-scale plasma proteomics offers opportunities to characterize disease susceptibility and improve prospective risk prediction, but transferring proteomic predictors across datasets remains challenging because measured protein sets differ across cohorts, study phases and assay configurations. Here we developed a sel...
Yonghyun Nam, Thomas M. Westbrook, J. Woerner et al.· medRxiv· 0 citations
Advances in high-throughput proteomics technologies have enabled the assessment of dynamic health states across biobank-scale cohorts. Disease prediction models built on these data have higher accuracy than baseline clinical models for a broad range of diseases, and provide avenues to understand disease pathogenesis. H...
S. Parsa, Y. Jee, M. Argentieri et al.· medRxiv· 0 citations
This large-scale proteome-wide Mendelian randomization study identified multiple plasma proteins with likely causal roles in EOS, implicating coagulation, platelet activation, extracellular matrix remodeling, and immune pathways in disease etiology.
A. Huynh, B. Gaynor, J. W. Cole et al.· medRxiv· 0 citations
Abstract The causes of most cancers remain unknown because the biological pathways underlying cancer development are poorly understood. Large-scale plasma proteomics offers a powerful strategy to uncover these pathways, identify biomarkers for cancer early detection, and discover novel therapeutic targets but has rarel...
J. Yarmolinsky, V. Viallon, V. Burk et al.· medRxiv· 0 citations
Blood metabolomics capture variation in biological aging, but the circulating proteins that underlie or accompany metabolomic aging and its links to disease and mortality remain underexplored. Here, we integrated metabolomics, proteomics and genetics from UK Biobank to characterize the protein architecture of metabolom...
X. Luo, C. Liu, Y. Xie et al.· medRxiv· 0 citations
This large-scale proteome-wide study not only reveals significant proteomic changes preceding SLD diagnosis but also establishes GDF15 as both a promising preclinical biomarker and opening new avenues for early intervention in at-risk individuals.